VALN - Valneva SE

-

$undefined

N/A

(N/A)

Valneva SE NasdaqGS:VALN Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.

Location: 6 rue Alain Bombard, Saint-Herblain, 44800, France | Website: https://valneva.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.043B

Cash

153M

Avg Qtr Burn

-11.73M

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.82%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IXCHIQ (VLA1553) Details
Chikungunya, Infectious disease

Approved

Quarterly sales

IXCHIQ (VLA1553) Details
Chikungunya, Viral infection

Phase 3

Update

IXCHIQ (VLA1553) Details
Chikungunya, Viral infection

Phase 3

Initiation

IXCHIQ (VLA1553) Details
Chikungunya, Viral infection

Phase 3

Initiation

Shigella4V2 (S4V2) Details
Shigella, Nasolabial fold lines

Phase 2

Data readout

VLA15 Details
Lyme disease, Bacterial infection

Phase 2

Data readout

VLA1601 Details
Viral infection, Zika virus

Phase 1

Data readout

VLA2001 Details
Infectious disease, COVID-19

Failed

Discontinued